Clinical Trial Update: Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the efficacy and safety of fingolimod 0.5 mg in Chinese patients with relapsing multiple sclerosis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Multiple Sclerosis (RMS) | Phase 4 | Status: COMPLETED | Results posted: 2025-08-29